Dendreon (NASDAQ:DNDN) shares soared on Friday, thanks to an incredibly bullish upgrade by Wall Street, with a price target essentially doubling Thursday's close. Fool health-care analyst David Williamson takes investors through the causes for Sanford Bernstein's sudden change in tone, and what it means for Dendreon.
The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.